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Erythrocyte (RBC) fatty acid compositions from populations with stable dietary habits but large
variations in RBC-arachidonic (AA) and RBC-docosahexaenoic acid (DHA) provided us with insight into
relationships between DHA and AA. It also enabled us to estimate the maternal RBC-DHA (mRBC-DHA)
status that corresponded with no decrease in mRBC-DHA during pregnancy, or in infant (i) RBC-DHA or
mRBC-DHA during the ﬁrst 3 months postpartum (DHA-equilibrium) while exclusively breastfeeding.
At delivery, iRBC-AA is uniformly high and independent of mRBC-AA. Infants born to mothers with low
RBC-DHA exhibit higher, but infants born to mothers with high RBC-DHA exhibit lower RBC-DHA than
their mothers. This switch from ‘biomagniﬁcation’ into ‘bioattenuation’ occurs at 6 g% mRBC-DHA. At
6 g%, mRBC-DHA is stable throughout pregnancy, corresponds with postpartum infant DHA-equili-
brium of 6 and 0.4 g% DHA in mature milk, but results in postpartum depletion of mRBC-DHA to 5 g%.
Postpartum maternal DHA-equilibrium is reached at 8 g% mRBC-DHA, corresponding with 1 g% DHA in
mature milk and 7 g% iRBC-DHA at delivery that increases to 8 g% during lactation. This 8 g% RBC-DHA
concurs with the lowest risks of cardiovascular and psychiatric diseases in adults. RBC-data from 1866
infants, males and (non-)pregnant females indicated AA vs. DHA synergism at low RBC-DHA, but
antagonism at high RBC-DHA. These data, together with high intakes of AA and DHA from our
Paleolithic diet, suggest that bioattenuation of DHA during pregnancy and postnatal antagonism
between AA and DHA are the physiological standard for humans across the life cycle.
& 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The long-chain polyunsaturated fatty acids (LCP) docosahex-
aenoic acid (DHA), eicosapentaenoic acid (EPA) and arachidonic
acid (AA) are structural components of membrane phospholipids
(PL), modulators of gene expression and precursors of eicosanoids
(AA, EPA), resolvins (AA, EPA, DHA) and (neuro)protectins
(DHA) [1]. DHA and AA are notably abundant in the central
nervous system and play important roles in fetal and infant
neurodevelopment [2]. Low status of LCP, notably LCPo3, is also
intimately related to cardiovascular and psychiatric diseases at
adult age [3]. Most Western countries are characterized by low
intakes of LCPo3 (especially EPA and DHA), which contrasts with
the evolution of our ancestors in a land–water ecosystem with
abundantly available LCPo3 and LCPo6 (especially AA) [4–9].
Higher LCP in circulating cord plasma lipids compared with
maternal plasma [named ‘biomagniﬁcation’[10]] and the loss of
maternal DHA during lactation [11] might be indicative for a low
LCPo3 status in Western countries [8].x: þ31 50 361 2290.
Kuipers).
sevier OA license.Pregnant and lactating women have higher LCP needs [12] to
support the development of the fetus and infant. This is notably
the case for DHA, which becomes synthesized from ALA with
difﬁculty [13,14]. Infants accrete AA in their brains especially in
early pregnancy, while DHA accretes rapidly from week 30 of
pregnancy to 2 years postpartum [15–20]. Transfer of LCP during
pregnancy and lactation occurs at the expense of the mother and
the resulting depletion of maternal stores during lactation has
been named the ‘maternal depletion syndrome’ [21,22]. Maternal
LCP depletion may especially occur at longer gestation [23], short
birth intervals, increasing parity and twin pregnancies [24–26].
Postpartum maternal LCP depletion seems notably to affect DHA,
and not AA. While AA in maternal plasma phospholipids (PL) and
erythrocytes (RBC) increases to prepregnancy values after deliv-
ery, there is a highly consistent postpartum decrease of maternal
plasma PL- and RBC-DHA in lactating compared to non-lactating
women [11,27]. A number of studies have demonstrated that a
low intake of LCPo3 during pregnancy results in slightly shorter
gestation, marginally lower birth weight and increased risk of
preterm delivery [28]. A low maternal DHA status, as encountered
in populations with low seafood consumption, has also been
associated with a higher incidence of postpartum depression
[29,30]. The causality is however uncertain, since randomized
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Fig. 1. Maternal (J) and infant (m) RBC-AA at delivery and after 3 months
lactation in mothers with low, intermediate or high ﬁsh intakes. Data are means
(72 s.e.m.) of total RBC fatty acids (g%) at delivery (t0) and 3 at months
postpartum (t1) for women with low ﬁsh intakes (n¼6 at delivery; n¼7 at
3 months PP) and their infants (n¼8, 6), women with intermediate ﬁsh intakes
(n¼27, 38) and their infants (n¼29, 38) and womenwith high ﬁsh intakes (n¼34, 60)
and their infants (n¼36, 61).
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been inconclusive [31–35]. Finally, a declining maternal DHA
status during pregnancy was suggested to be involved in com-
promised maternal selective attention, which is a key component
of cognition [36]. Other RCTs aimed at improvement of infant
neurodevelopment by supplementation of pregnant women or
their infants with LCP [37]. These maternal DHA supplementation
studies show at most subtle effects [38–42], which is in line with
meta-analyses of postnatal LCP supplementation of formula milk
for preterm and term infants [43,44]. However, two large recent
trials that were not yet included in the meta-analyses, reported
positive inﬂuences on infant visual acuity [45,46]. The outcomes
of RCTs and meta-analyses contrast with the positive relations
between neonatal brain DHA and cognitive and behavioral per-
formance that are noted in the combined human and animal
studies [2].
We present an integrated overview of RBC-AA and DHA data,
deriving from mothers and infants at delivery and after 3 months
of exclusive lactation. RBC fatty acids (FA) are considered to be
reliable parameters of long term dietary intakes [47], The samples
were obtained from three tribes living in Tanzania. The study
populations are characterized by life-time stable dietary intakes.
Their intake of ﬁsh ranges from very low (mean 0 times/week;
SD 0.7), to intermediate (372 times/week) to high (572 times/
week) [48,49]. Their RBC-FA compositions provided us with
insight into the perinatal relationships between maternal and
infant DHA and AA status, and enabled us to estimate the
maternal DHA status at which either the infant or its mother
reaches a state of DHA equilibrium, which implies that there were
no changes in RBC-DHA from delivery until 3 months lactation.
We ﬁnally focused at the relationship between RBC-AA and
RBC-DHA as derived from the many RBC data that we have
collected during the past 20 years from populations with a wide
range in RBC-DHA.2. Intrauterine biomagniﬁcation of AA may aim at uniform
fetal AA status
We found consistently higher AA in newborn umbilical cord
blood RBC (in g/100 g; g% FA) as compared to the corresponding
maternal RBC (Fig. 1). This ‘biomagniﬁcation’ of AA [10] was
independent of maternal AA status at delivery and at 3 months
postpartum (Fig. 2A and B). Biomagniﬁcation of AA is in line with
data from many others who studied plasma PL-AA [27,50] or
RBC-AA [51–53]. Higher infant RBC-AA than maternal RBC-AA
was e.g. previously found by us in Dominica [54] and by
Vlaardingenbroek and Hornstra in The Netherlands [53]. Most
importantly however, we noticed a remarkably uniform, high
infant RBC-AA at delivery (Fig. 1). This low inter-individual
variation occurred despite the sizeable between-tribe differences
of maternal RBC-AA and RBC-DHA (Fig. 3). Consequently, AA
biomagniﬁcation seems to aim at a uniform infant AA status
during pregnancy, rather than just causing higher AA in infants
than in their mothers, which may emphasize the importance of a
certain infant prenatal AA status. Intrauterine AA has been
implicated in fetal growth [55,56], while AA also rapidly accretes
in the fetal brain [16–20,57].
After delivery, maternal RBC-AA increased consistently during
3 months of exclusive breastfeeding (Fig. 1), possibly because of
discontinued AA utilization by the placenta [58,59], discontinued
transport to the fetus, or both. The maternal increase of AA status
was accompanied by a drop in infant AA status, which might
represent the transition of the infant’s RBC-FA composition to adult
proportions and coincides with the postpartum changes in the
composition of the infant’s RBC-PL species [60,61]. Mechanistically,the postnatal RBC-AA decrease might also result from the discon-
tinued AA transport across the placenta and from the change of
hormonal milieu that accompanies delivery. The latter is likely to
inﬂuence FA enzymatic activities. It was e.g. shown that the
infants’ LCP-synthetic activity decreases drastically after delivery
[14]. Even the relatively high milk AA contents in some of the
Tanzanian tribes (0.37 g% in Maasai vs. 0.80 g% in the Pare-like
Nyiramba [62]) were unable to prevent this decrease in infant RBC-
AA. The rapid postnatal drop of infant RBC-AA raises the question
whether milk AA is at all intended to sustain infant AA status after
delivery. This suggestion is in line with Hsieh et al.[63], who
recently showed that central nervous system (CNS) AA contents in
baboon neonates are tightly controlled at the level of incorporation
or utilization, that CNS AA levels were unaffected by (postnatal)
dietary AA and decreased in all CNS structures with age. Taken
together, a uniformly high infant AA status seems notably impor-
tant during pregnancy, which contrasts with the predominant
accretion of DHA in the infant’s brain after birth.3. Where DHA biomagniﬁcation turns into bioattenuation
during pregnancy
Infants born to mothers with low and intermediate ﬁsh intakes
and DHA status exhibited higher RBC-DHA contents as compared
to their mothers (Fig. 3), which has been named ‘biomagniﬁca-
tion’ [10]. However, in our study this biomagniﬁcation occurred
only up to about 6 g% RBC-DHA (Fig. 4A). Beyond this turning
point, infant RBC-DHA was mostly lower than maternal RBC-DHA,
suggesting ‘bioattenuation’, rather than biomagniﬁcation. The
previously published mean RBC-DHA values for the Dutch popu-
lation (with low ﬁsh intakes) [53] and for the Dominican popula-
tion (Caribbean Sea; with high ﬁsh intakes; [54]) proved highly
consistent with the suggested mother–infant RBC-DHA relation at
delivery. Bioattenuation has also been noticed in a maternal ﬁsh
oil supplementation study conducted by Dunstan et al. [64],
who referred to it as ‘saturation’. The present information from
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Fig. 2. Relations between maternal and infant RBC-AA at delivery (A) and after 3 mo lactation (B) for mother–infant pairs with low (m, n¼6), intermediate (J, n¼24) and
high (’, n¼33) ﬁsh intakes. Mean data for Dominican (n¼7;&) and Dutch (n¼183; D) mother–infant couples are derived from Refs. [53,54], respectively. PP, postpartum,
dotted line represents y¼x for ‘equal AA sharing’.
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Fig. 3. Maternal (J) and infant (m) RBC-DHA at delivery and after 3 months
lactation in mothers with low, intermediate or high ﬁsh intakes. Data are means
(72 s.e.m.) of total RBC fatty acids (g%) at delivery (t0) and 3 at months
postpartum (t1); for n, see Fig. 1.
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biomagniﬁcation is conﬁned to the low maternal DHA status that
is typically encountered in most Western countries.4. Infant RBC-DHA equilibrium
The postpartum mother-to-infant DHA transfer via the milk
was unable to prevent an RBC-DHA drop in the infants born to
mothers with low and intermediate ﬁsh intakes, but did enable a
postpartum RBC-DHA increase in infants from the mothers withhigh ﬁsh intakes (Fig. 3). Postpartum infant DHA equilibrium may
therefore be reached at DHA intakes that are somewhat below those
of our study group with an average ﬁsh intake of 5 times/week.
Using the joined data of all mothers and infants we estimated that
mothers with an RBC-DHA status of about 6 g% in early pregnancy
will have an RBC-DHA of about 6 g% at delivery and will give birth to
infants with about 6 g% RBC-DHA [48] (Fig. 4A). This 6 g% infant
RBC-DHAwill then remain constant during lactation, but the mother
will under these circumstances lose DHA to reach a maternal RBC-
DHA of about 5 g% after 3 months of exclusive lactation (Fig. 5A).
Postnatal infant DHA equilibrium, i.e. a maternal RBC-DHA of 6 g%
at delivery, goes along with a mature milk DHA level of about
0.4 g% (Kuipers, unpublished). The combination of a state of infant
DHA-equilibrium and maternal DHA losses during lactation illus-
trates a postnatal DHA surge via the milk and can therefore be
considered as a genuine form of postnatal DHA-biomagniﬁcation.
We conclude that a maternal DHA status corresponding with an
RBC-DHA status of 6 g% predicts a state of DHA equilibrium in her
infant during 3 months postpartum.5. Maternal RBC-DHA equilibrium
Maternal RBC-DHA was consistently lower after 3 months of
lactation as compared to delivery, suggesting that the mothers
were losing DHA to their infants via the milk (Fig. 3). However,
although maternal RBC-DHA decreased in all groups, the decrease
was lowest in mothers with the highest ﬁsh intakes (i.e. 5 times/
week). This implies that maternal DHA equilibrium may occur at
ﬁsh intakes that exceed those encountered by us in the popula-
tion with the highest ﬁsh intakes. By extrapolating the data of our
3 Tanzanian groups, we estimated that this equilibrium may be
reached at a maternal RBC-DHA at delivery of about 8 g% (Fig. 4B).
This state of maternal postnatal DHA equilibrium corresponds
with a maternal RBC-DHA status of 8 g% in early pregnancy [48],
an infant RBC-DHA of about 7 g% at delivery that increases to 8 g%
at 3 months postpartum and a mature milk content of about 1 g%
DHA (Kuipers, unpublished) (Fig. 5B). We coined this lower infant
RBC-DHA compared to maternal RBC-DHA bioattenuation [48].
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Fig. 4. Relations between maternal and infant RBC-DHA (in g%) at delivery (A) and after 3 months of lactation (B) for mother–infant pairs with low (m, n¼6), intermediate
(J, n¼24) and high (’, n¼33) ﬁsh intakes. Dotted lines indicates y¼x for ‘equal DHA sharing’. Data for Dominican (n¼7;&) and Dutch (n¼183; D) mother–infant pairs
are derived from Refs. [53,54] respectively. The point of intersection of y¼x with the trend line y¼0.59þ2.29 (R2¼0.61; po0.001) in Panel A is at an RBC-DHA of about
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DHA content of 0.4 g%. Mother and infant are at equilibrium at delivery, but the mother loses DHA during lactation. Panel B: maternal RBC-DHA equilibrium from delivery
to 3 months postpartum is reached at 8 g% maternal RBC-DHA. This corresponds with an infant RBC-DHA of 7 g% in early pregnancy, an infant RBC-DHA of 8 g% after
3 months lactation and a mature milk DHA content of 1.0 g%. Infant RBC-DHA is lower than that of its mother at delivery (bioattenuation), but the infant reaches adult
RBC-DHA contents within 3 months of lactation.
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increases rapidly to adult levels of about 8 g% during 3 months
of lactation. Bioattenuation might illustrate the importance of
limiting transplacental DHA transport at high maternal ﬁsh
intakes, while the subsequent postnatal period is characterized
by a mother-to-infant surge of DHA via the milk in all groups. This
postpartum mother-to-infant DHA surge clearly occurs at the
expense of the mother unless she had reached a steady state RBC-
DHA of 8% or higher from high lifetime ﬁsh intakes. The postnatal
DHA transfer from the mother to her infant coincides with a more
rapid postnatal accretion of DHA in the infant brain, compared
with AA [16–20,57] and may therefore illustrate the increasing
importance of DHA for structural and other purposes notably
after birth. Another function of the postnatal DHA-surge might be
the rapid initiation of postnatal competition of DHA with AA inthose organs that are sensitive to DHA vs. AA competition (see
below).6. What maternal DHA status is best?
The question arises as to what maternal DHA status is best for
both the mother and her infant. At present, there is consensus on
recommending an average DHA intake of at least 200 mg/day
during pregnancy and lactation [28]. A number of studies have
indicated that the intake of ﬁsh and ﬁsh oils during pregnancy
result in slightly longer gestation, marginally higher birth weight
and a reduced risk of preterm delivery [28]. However, little
information can be derived from the current RCTs with DHA
during pregnancy that targeted infant neurodevelopment.
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top of a baseline diet containing 200–300 mg DHA/day by Helland
et al. [40–42] showed no differences in cognitive development at
6 and 9 months, and a promising higher IQ at 4 years of age, but
not at 7 years. They also found that neonates with mature EEG
had higher DHA in umbilical plasma PL, compared with counter-
parts with less mature EEG [40]. A higher maternal plasma PL-
DHA correlated with sequential processing, but milk-DHA did not
correlate with IQ scores at 7 years [42]. These outcomes were in
line with the negative outcomes for the associations between
umbilical plasma PL- and RBC-DHA and infant cognitive develop-
ment at 4 and 7 years in another study [38,39]. Additional studies,
however, revealed that supplementation of pregnant women with
ﬁsh oil might inﬂuence the infants’ visual maturation and acuity
[65–67] and newborn sleep pattern maturity [68]. Thus, results of
maternal DHA supplementation studies show at most subtle
effects, which is in line with the results of meta-analyses of
postnatal LCP supplementation of formula milk for preterm and
term infants [43,44]. Two recent large trials with postnatal DHA
supplementation, however, again reported positive inﬂuences on
infant visual acuity [45,46]. The outcomes of most RCTs contrast
with the positive relations between neonatal brain DHA and
cognitive and behavioral performance that are noted in the
combined human and animal studies [2]. The discrepancy might
relate with e.g. differences in frequencies of polymorphisms in the
desaturase enzymes and the lack of dose-adjustment to differ-
ences in the individual baseline maternal and infant DHA status.
Another factor might be the relatively short-term supplementa-
tion of low doses of DHA that are not able to cause a stable high
maternal and infant DHA status, which is needed to arrive at
beneﬁcial effects of DHA. Therefore, from the perspective of infant
neurodevelopment, the question remains currently unresolved
and may need a broader view that takes into account studies of
relationships between adult DHA status and functional outcomes.
High milk and RBC-DHA contents are in line with the optimal
RBC-DHA status as proposed for the prevention of psychiatric and
cardiovascular diseases at adult age. Epidemiological studies have
linked high ﬁsh consumption, EPAþDHA intakes or EPAþDHA
status, to a reduction in affective disorders [69], cognitive impair-
ment [70], Alzheimers disease [71] and postpartum depression
[29]. An RBC-(EPAþDHA)Z8 g%, also named the omega-3 index,
as found in healthy subjects in Japan, seems an appropriate target
to minimize major depressive disorders and bipolar depression
[69]. Meta-analyses of RCTs are positive, but heterogeneous, for
depression [72,73], positive for cognitive impairment [74], but
negative for Alzheimer’s disease [75]. The relation between
LCPo3 and postpartum depression has not been substantiated
by RCTs [31–35], but none of these studies concomitantlyRBC 
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Fig. 6. The relation between RBC-DHA and RBC-AA for 1866 infants, males and preg
47.5 g%.investigated the course of RBC-DHA as a proxy of the maternal
depletion syndrome. A more consistent picture emerges from
studies between the relation of LCPo3 with cardiovascular dis-
ease. For example, the study by Helland et al. [40–42] showed a
lower cholesterol/HDL-cholesterol ratio in the women supple-
mented with cod liver, compared to corn oil [76]. Various RCTs
in notably secondary prevention of cardiovascular disease have
indicated the beneﬁcial effects of LCPo3 supplementation [77,78].
These have led to the advice of at least 2 times ﬁsh per week (about
450 mg LCPo3/day) for the general population and an intake of 1 g
EPAþDHA for those with cardiovascular disease [79]. There is
evidence that daily LCPo3 intakes 4450 mg are beneﬁcial for
the lowering of heart rate, blood pressure and triglycerides and
to reach maximum antithrombotic effects [80]. Subjects with
RBC-DHA 48 g% (omega-3 index 410 g%) may reach the lowest
risk for acute coronary syndrome and sudden cardiac death [81–85].
High milk DHA and RBC-DHA contents also comply with the
high intakes of EPA and DHA, as calculated from the presumed
diet of our Paleolithic ancestors [7,8]. These are likely to have
evolved in a water–land ecosystem in East-Africa [4–9], where the
fossil record indicates that they exploited aquatic resources. It is
therefore likely that our genome has, especially during the about
2.5 millions years of evolution since homo erectus, become
adapted to a diet [86,87] that was rich in LCPo3 and LCPo6 from
our aquatic niche. The presumed high DHA intakes by our
ancestors are likely to have resulted in maternal stores that
prevented depletion during lactation and sustained a stable
DHA transfer to the developing infant, where DHA plays an
important role in the maturation of the brain [20], retina [88]
and other central nervous structures [63]. Taken together, our
ﬁnding of maternal DHA equilibrium at an RBC-DHA of 8 g% is in
line with the optimal RBC-DHA status that has been suggested for
the lowest risk of cardiovascular and psychiatric diseases, and
thereby adds to the contention that homo sapiens has evolved in a
land–water ecosystem.7. DHA and AA are synergistic at low postpartum DHA status
and antagonistic at high DHA status
The relationship between DHA and AA has been subject to
many investigations and both synergistic [89–92] and antagonis-
tic relations [93,94] have been reported. Horrobin et al. [95] were
the ﬁrst to note a synergistic relation between EPA and AA at a
low administered EPA dosage and an antagonistic relationship
between EPA and AA at high EPA dosage [95]. We explored this
relationship in our data from Tanzania and found synergism
between DHA and AA at low DHA status and antagonism at highDHA (g%)
y = 0.121x +12.83
R2 = 0.007, p<0.001
y = -1.07x +21.6
R2 = 0.10, p<0.010
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dataset of 890 umbilical veins and arteries and in our dataset of
RBC-FA deriving from 1866 infants, males and pregnant and non-
pregnant females (Fig. 6) [96]. Synergism/antagonism between
DHA and AA seems therefore not limited to pregnancy and
lactation but occurs throughout the entire life cycle. As suggested
by Horrobin et al. [95], optimum health may require raising both
o3 and o6 fatty acids from low status and it is conceivable that
synergism/antagonism actually aims at a certain balance between
LCPo3 and LCPo6. We recently estimated that our hunting–
gathering ancestors living in a water–land ecosystem had daily
intakes of gram amounts of AA, EPA and DHA [7], which contrasts
with the current daily (French) intakes of about 200 mg AA and
275 mg DHA (men) from a typically Western diet [97]. It is in this
respect of importance to note that the above noted seemingly
optimal RBC-DHA levels of 48 g% [81–85] reside in the antag-
onistic area of the bell-shaped DHA–AA relation (Fig. 6). This
suggests that an antagonistic relation between DHA and AA might
have been the physiological standard for human beings and that a
high DHA intake is necessary to keep AA levels in check, possibly
to maintain the balance between the proinﬂammatory and anti-
inﬂammatory metabolites of AA, EPA and DHA [1].8. Merging intrauterine biomagniﬁcation/attenuation and
postnatal synergism/antagonism
We suggest that the intrauterine DHA biomagniﬁcation noted
in mothers with low ﬁsh intakes aims at a synergistic increase of
fetal DHA status to maintain a balance with the much easier
formed AA. The subsequent bioattenuation at higher DHA status,
as occurring in mothers with high ﬁsh intakes, may on its turn
prevent abundant passage of DHA across the placenta, and
thereby an antagonistic decrease of fetal AA status in competi-
tion-sensitive fetal organs. Such a barrier might be important
since AA is implicated in fetal growth [12,18,55,56] and rapidly
accretes in the fetal brain [16–20,57]. With increasing gestation,
DHA becomes increasingly important for neurodevelopment and
even more so after birth [12,18,88]. The postnatal DHA surge via
the milk may therefore be regarded as a form of postnatal
biomagniﬁcation, but this surge is unable to prevent a postnatal
RBC-DHA drop in infants born to mothers with low and inter-
mediate ﬁsh intakes. Analogous to the intrauterine period, the
resulting low DHA status in infants born to women with low ﬁsh
intakes might have synergistically lowered their RBC-AA, while
the high DHA status of the infants born to mothers with high ﬁsh
intakes might have lowered their RBC-AA in an antagonistic
manner. We suggest that the intrauterine regulation of DHA
status via biomagniﬁcation/attenuation is likely to conserve the
important role of AA in the developing infant during pregnancy,
while the postnatal DHA surge via the milk aims at the suppres-
sion of AA in an antagonistic manner.9. Conclusions
Our data indicate that fetal AA status is high and tightly
regulated, probably to support adequate fetal growth and neuro-
logical development. Biomagniﬁcation of DHA across the placenta
occurs at the expense of the mother and may aim at a synergistic
increase of fetal AA and DHA status. Bioattenuation of DHA during
pregnancy may on the other hand aim at the prevention of
competition of DHA with AA in the fetus at high maternal ﬁsh
intakes. A maternal RBC-DHA of 6 g% seems sufﬁcient to maintain
a constant infant DHA status during pregnancy and notably
lactation, but a maternal RBC-DHA of at least 8 g% is needed toprevent maternal DHA depletion notably during lactation. The
latter DHA status concurs with the lowest risks of cardiovascular
and psychiatric diseases in adults. Taken together, these data and
also the high intakes of LCPo3 and LCPo6 from the presumed diet
of our Paleolithic ancestors suggest that bio-attenuation of DHA
during pregnancy and postnatal antagonism of AA status by
dietary DHA are the physiological standard for human beings
across the life cycle.References
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